Understanding how gene changes contribute to early Inflammatory Bowel Disease
Mechanisms of Duox2 variants in the pathogenesis of preclinical IBD
This project aims to discover how specific gene variations in the gut may lead to the early stages of Inflammatory Bowel Disease, hoping to find new ways to prevent it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11103345 on NIH RePORTER |
What this research studies
Inflammatory Bowel Disease (IBD) is a challenging gut condition, and finding ways to diagnose and treat it early could greatly improve outcomes. This research focuses on understanding the very first signs of imbalance between gut microbes and the gut lining in people who are at risk for IBD. We are particularly interested in a gene called DUOX2, which helps maintain a healthy gut environment. Changes in this gene are often seen in early IBD and may make individuals more susceptible to the disease. By learning how these gene changes affect gut health, we hope to identify new targets for treatments that could stop IBD before it fully develops.
Who could benefit from this research
Good fit: This research is relevant to individuals at risk for Inflammatory Bowel Disease, particularly those with specific genetic variations in the DUOX2 gene.
Not a fit: Patients who already have established Inflammatory Bowel Disease may not directly benefit from this early prevention-focused research.
Why it matters
Potential benefit: If successful, this work could lead to new ways to identify individuals at risk for IBD and develop treatments to prevent the disease from starting.
How similar studies have performed: Previous work has shown a link between DUOX2 defects and IBD susceptibility in both animal models and human populations, suggesting a promising direction for this research.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Kao, John Y — University of Michigan at Ann Arbor
- Study coordinator: Kao, John Y
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.